Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Head and Neck Oncology
  •  Colorectal Cancer
  •  Urological Cancers
  •  Neoadjuvant Therapy
  •  Bladder Cancer
  •  Targeted Therapy
  •  Breast Cancer
  •  Radiation Oncology


Citation: Clin Oncol. 2016;1(1):1101.DOI: 10.25107/2474-1663.1101

Cardiovascular Co-Morbidity and the Outcome after Myeloablative Hematopoietic Stem Cell Transplantation for Advanced Lymphoma

Hsueh Ju Lu, Ya-Ching Chen, Ming-Huang Chen, Wei-Hsin Chen, Jui-Hung Kao, Chia-Ping Shen, Feipei Lai, Chi Ying F. Huang, Yu-Feng Hu and Peter Mu-Hsin Chang

Department of Internal Medicine, Chung Shan Medical University Hospital, Taiwan
Department of Oncology, Taipei Veterans General Hospital, Taiwan
Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taiwan
Department of Cardiovascular Research Institute, National Yang-Ming University, Taiwan
Department of Medicine, Chung Shan Medical University, Taiwan
Department of Medicine, National Yang-Ming University, Taiwan
Department of Biomedical Electronics and Bioinformatics, National Taiwan University, Taiwan
Department of Medical Research, Show Chwan Memorial Hospital, Taiwan
Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taiwan
These authors contribute equally to this work.

*Correspondance to: Yu-Feng Hu 

 PDF  Full Text Original Article | Open Access


We evaluated cardiovascular-associated co-morbidities systematically in patients undergoing hematopoietic stem cell transplantation (HCT) for lymphoma. In this study, 101 lymphoma patients (41.3 ± 13.6 years) receiving salvage myeloablative HCT with high-dose conditioning treatments were recruited. Cardiovascular associated factors were reviewed and correlated to outcome after HCT. The mean follow-up period was 1074.8 ± 739.2 days. The Overall Survival (OS) rate was 68.3% and the 3-month survival rate was 89.1%. Multivariate analysis revealed that the independent risk factors for OS were High Sensitivity C-Reactive Protein (HsCRP), Abnormal Regional Wall Motion (ARWM), age, and Eastern Cooperative Oncology Group (ECOG) performance status. Combination of the 4 risk factors significantly increased the predictive value for OS. High HsCRP levels were associated with higher cumulative tumor-related mortality (P=0.045). ARWM was associated with both higher cumulative tumor-related mortality (P=0.01) and non-relapse mortality (P=0.027). In conclusions, ARWM and HsCRP were important predictors for long-term survival in lymphoma patients undergoing HCT.


Abnormal regional wall motion; High sensitivity c-reactive Protein; Hematopoietic stem cell transplantation

Cite the Article:

Lu HJ, Chen Y-C, Chen M-H, Chen W-H, Kao J-H, Shen C-P, et al. Cardiovascular CoMorbidity and the Outcome after Myeloablative Hematopoietic Stem Cell Transplantation for Advanced Lymphoma. Clin Oncol. 2016; 1: 1101.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Characteristics of Adult Glioblastoma in Kuwait
 Abstract  PDF  Full Text
Application of First-Line Steady-State Mobilization vs. Conventional Chemotherapy Mobilization for Peripheral Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma Patients
 Abstract  PDF  Full Text
View More...